An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and Vomiting

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2021 Sep 27

PMID 34566427

Citations 1

Authors

Yilan Jin

Xiaorong Li

Caihong Jiang

Jun Zhao

Guang Liu

Hui Li

Gaowa Jin

Quanfu Li

Affiliations

Soon will be listed here.

Abstract

The occurrence and severity of chemotherapy-induced nausea and vomiting (CINV) are influenced by many factors; this includes therapeutic factors, such as the dose, administration mode, and chemotherapeutic agent emetogenicity, as well as patient-related risk factors, such as the gender, age, alcohol consumption history, and anxiety level. However, these factors cannot fully explain the individual CINV differences. In recent years, the correlation between gene polymorphism and CINV has been a hot research topic; the present paper reviews current research on CINV-related gene polymorphisms, and the results indicate that the use of gene polymorphism for the optimization of CINV efficacy is of important clinical significance.

Citing Articles

A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective.

Ullah I, Ayaz M Pharmacol Rep. 2023; 75(5):1126-1137.

PMID: 37584820 DOI: 10.1007/s43440-023-00514-z.

References

Kang G, Kim K, Shim H, Hwang J, Bae W, Chung I . Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients. Asia Pac J Clin Oncol. 2016; 13(1):53-60. DOI: 10.1111/ajco.12575. View

Yokoyama S, Tamaru S, Tamaki S, Nakanishi D, Mori A, Yamakawa T . Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy. Clin Breast Cancer. 2017; 18(2):e157-e165. DOI: 10.1016/j.clbc.2017.05.013. View

Singh K, Dhruva A, Flowers E, Kober K, Miaskowski C . A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting. Crit Rev Oncol Hematol. 2017; 121:51-61. PMC: 5777158. DOI: 10.1016/j.critrevonc.2017.11.012. View

Lee A, Shi Q, Pavey E, Alberts S, Sargent D, Sinicrope F . DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014; 106(12). PMC: 4271081. DOI: 10.1093/jnci/dju298. View

Sommariva S, Pongiglione B, Tarricone R . Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. Crit Rev Oncol Hematol. 2015; 99:13-36. DOI: 10.1016/j.critrevonc.2015.12.001. View

Jin Y, Jin G, Zhao J, Jiang C, Zhao L, Jiang Y . Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV. Pharmgenomics Pers Med. 2021; 14:867-875. PMC: 8289460. DOI: 10.2147/PGPM.S317229. View

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E . 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119-v133. DOI: 10.1093/annonc/mdw270. View

Ward M, Kotasek D, McKinnon R . Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008; 9(8):1027-33. DOI: 10.2217/14622416.9.8.1027. View

Hammer C, Fasching P, Loehberg C, Rauh C, Ekici A, Jud S . Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics. 2010; 11(7):943-50. DOI: 10.2217/pgs.10.67. View

10.

Zoto T, Kilickap S, Yasar U, Celik I, Bozkurt A, Babaoglu M . Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter. Basic Clin Pharmacol Toxicol. 2014; 116(4):354-60. DOI: 10.1111/bcpt.12334. View

11.

Madi A, Fisher D, Maughan T, Colley J, Meade A, Maynard J . Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer. 2018; 102:31-39. DOI: 10.1016/j.ejca.2018.07.009. View

12.

Mosa A, Hossain A, Lavoie B, Yoo I . Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. Front Pharmacol. 2020; 11:329. PMC: 7138899. DOI: 10.3389/fphar.2020.00329. View

13.

Yang Y, Botton M, Scott E, Scott S . Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing. Pharmacogenomics. 2017; 18(7):673-685. PMC: 5591463. DOI: 10.2217/pgs-2017-0033. View

14.

Wigle T, Tsvetkova E, Welch S, Kim R . and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics. 2019; 11(5). PMC: 6572291. DOI: 10.3390/pharmaceutics11050199. View

15.

Yokoi M, Tsuji D, Suzuki K, Kawasaki Y, Nakao M, Ayuhara H . Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer. 2017; 26(5):1505-1513. DOI: 10.1007/s00520-017-3974-3. View

16.

Pud D, Har-Zahav G, Laitman Y, Rubinek T, Yeheskel A, Ben-Ami S . Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer. Breast Cancer Res Treat. 2014; 144(1):123-31. DOI: 10.1007/s10549-014-2832-y. View

17.

Tremblay P, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K . Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003; 21(11):2147-55. DOI: 10.1200/JCO.2003.05.164. View

18.

Tzvetkov M, Saadatmand A, Bokelmann K, Meineke I, Kaiser R, Brockmoller J . Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2010; 12(1):22-9. DOI: 10.1038/tpj.2010.75. View

19.

Kitamura T, Qian B, Soong D, Cassetta L, Noy R, Sugano G . CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015; 212(7):1043-59. PMC: 4493415. DOI: 10.1084/jem.20141836. View

20.

Sprowl J, Ness R, Sparreboom A . Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet. 2012; 28(1):19-27. PMC: 3705946. DOI: 10.2133/dmpk.dmpk-12-rv-073. View